|Bid||0.6000 x 3000|
|Ask||0.6209 x 900|
|Day's Range||0.5890 - 0.6392|
|52 Week Range||0.5170 - 3.3200|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 02, 2022 - Mar 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1,168.72|
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Optimizes Development Strategy with Study Initiations and Data Announcements Expected throughout 2022 Announces Plan to Initiate Randomized Phase 2 Study for NUC-3373 in Colorectal Cancer Extends Anticipated Cash Runway into 2025 EDINBURGH, United Kingdom, April 27, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the fourth quarter and year ended December 31, 2021 and provided an update on its broad clinical program with its transformative ProTide therapeutics.
On BioNTech's (BNTX) fourth-quarter earnings call, investors' focus is expected to be on the sales performance of Comirnaty, its COVID-19 vaccine developed in partnership with Pfizer.